In 2015, world leaders made a landmark commitment to end epidemics of AIDS, tuberculosis, malaria and other communicable diseases by 2030, and to achieve universal health coverage and equitable access to medicines and vaccines. These pledges formed the third goal of the United Nations Sustainable Development Goals (SDGs), aimed at ensuring healthy lives and well-being for all. Yet eight years later, the global community is falling short, and in some areas, progress has even reversed.
Early signs after the SDG launch suggested momentum. Deaths among newborns and children under five declined, new HIV infections fell, and access to universal health care expanded—albeit more slowly than before 2015. But the COVID-19 pandemic, ongoing wars, and other disruptions have since reversed long-standing gains. For the first time in decades, global life expectancy is declining. Diseases once close to eradication, such as polio, have resurged, while malaria cases have been rising since 2016. The setbacks are a stark reminder that commitments alone cannot guarantee outcomes.
In response to these challenges, Nature and other journals within the Nature Portfolio have emphasized their commitment to advancing the SDGs, particularly through scientific research that translates into policy and practice. This week marks the launch of a new publication, Nature Health, designed specifically to bridge the gap between health research and real-world implementation. In its inaugural editorial, Nature Health states that it will prioritise research with practical impact, especially work conducted in resource-limited settings in low- and middle-income countries (LMICs) and deprived communities elsewhere.
The timing of the journal’s launch underscores a troubling paradox: scientific progress in medicine is accelerating at an unprecedented rate, yet stark disparities in health outcomes persist. Breakthroughs such as gene editing, 3D bioprinting, high-resolution imaging, and robotic surgery promise transformative improvements in diagnosis and treatment. However, billions of people, particularly in LMICs, still lack access to basic public-health services such as clean water and sanitation.
The global health financing landscape has also deteriorated sharply. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, describes an “unprecedented crisis” in funding. In 2025, international health funding for Africa is projected to fall below $40 billion, down from $80 billion in 2021, as wealthier nations cut aid budgets. This dramatic reduction threatens to undermine progress and deepen inequalities.
The crisis has also been framed as an opportunity for countries to reduce dependence on foreign aid and build resilient health systems. Tedros and others argue that domestic capacity must be strengthened through investment in local research and innovation. In a Comment article in Nature Health, the inaugural cohort of Calestous Juma Science Leadership Fellows—African scientists supported by the Gates Foundation—calls for focused action across six areas, with a leading recommendation that the private sector take a more active role in research and development.
The Fellows’ call has particular resonance for business leaders, who are increasingly influential in shaping health-care innovation. Their engagement could help fill the funding gap left by retreating international donors, and provide sustained support for public sector health systems. It also highlights a growing recognition that the private sector has a responsibility to contribute to effective regulation, innovation, and long-term public health goals.
Artificial intelligence is also increasingly shaping the health-care landscape. In a Perspective article in Nature Health’s launch issue, researchers describe how large language models (LLMs) are already improving diagnostics and supporting decision-making in LMICs. Yet adoption faces major hurdles, including weak digital infrastructure and a lack of relevant laws and regulations. The authors call for rigorous evaluation studies—such as randomized controlled trials—and economic analyses to validate claims of effectiveness and cost-efficiency.
The potential of AI is further complicated by the growing use of synthetic data—algorithm-generated datasets designed to mimic real-world statistics. Nature has previously reported that synthetic data could help overcome data scarcity in LMICs and reduce the need for extensive ethical review. However, the new Nature Health article stresses that barriers to adoption remain high, and that robust evaluation is urgently needed.
As the world struggles to meet its SDG commitments, Nature and the broader scientific community are reaffirming their role in advancing health equity. Through research, policy engagement, and a renewed focus on implementation, they aim to help ensure that health and well-being become a reality for all, rather than a goal slipping further out of reach.
